SCHEMBL2400969

SCHEMBL2400969

O=C(NCc1cccs1)C1=NOC2(CCN(S(=O)(=O)c3ccc(Cl)cc3)CC2)C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
PKM P14618 2/20 0.58
SMN1; SMN2 Q16637 4/20 0.53
LMNA P02545 3/20 0.53
TP53 P04637 1/20 0.53
POLB P06746 5/20 0.48
KDM4E B2RXH2 2/20 0.47
GAA P10253 3/20 0.46
MAPK1 P28482 2/20 0.45
CTDSP1 Q9GZU7 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MEN1 O00255 1/20 0.44
BLM P54132 1/20 0.44
KMT2A Q03164 1/20 0.44
USP2 O75604 2/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
F2 P00734 1/20 0.44
THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2400765 0.89 THRB (0.51) ALDH1A1PKMSMN1; SMN2LMNATP53
SCHEMBL2400331 0.88 KDM4E (0.54) ALDH1A1PKMSMN1; SMN2LMNATP53
SCHEMBL6409896 0.85 ALDH1A1 (0.56) ALDH1A1PKMSMN1; SMN2LMNATP53
SCHEMBL2401910 0.80 ALDH1A1 (0.59) ALDH1A1PKMSMN1; SMN2TP53POLB
SCHEMBL2585376 0.80 ALDH1A1 (0.56) ALDH1A1PKMSMN1; SMN2LMNATP53
SCHEMBL2575305 0.79 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2LMNATP53POLB
SCHEMBL2400983 0.79 SMN1; SMN2 (0.44) ALDH1A1PKMSMN1; SMN2LMNATP53
SCHEMBL6410300 0.78 SMN1; SMN2 (0.62) ALDH1A1SMN1; SMN2LMNAPOLBKDM4E
SCHEMBL2403261 0.78 HTR1A (0.45) ALDH1A1KDM4E
SCHEMBL2401811 0.78 MAPT (0.50) ALDH1A1PKMSMN1; SMN2LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US claimed
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US disclosed
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods SULT1E1, DECR1, CYP8B1 ALDH1A1 156/4885PKM 1372/4885SMN1; SMN2 1407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.